Novartis AG stock (CH0012005267): Spin-off, oncology focus and pipeline updates in the spotlight

Novartis AG is reshaping its portfolio after the Sandoz spin-off and sharpened focus on innovative medicines. Recent earnings, product approvals and pipeline news keep the Swiss pharma heavyweight on the radar of global and US-focused healthcare investors.

Novartis AG has been in focus for global healthcare investors as the Swiss pharmaceutical group continues to streamline its portfolio after the completed spin-off of its generics unit Sandoz and concentrates more tightly on higher-margin innovative medicines and oncology. The company has recently reported quarterly results and continued to highlight progress in key growth drivers such as cardiovascular and cancer therapies, according to company disclosures and financial reports from spring 2025.

As of: 26.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Novartis
• Sector/industry: Pharmaceuticals, biotechnology
• Headquarters/country: Switzerland
• Core markets: Global prescription drugs with focus on Europe, US and key international markets
• Key revenue drivers: Innovative medicines, oncology portfolio, cardiovascular and immunology treatments
• Home exchange/listing venue: SIX Swiss Exchange (NVS on NYSE via ADRs)
• Trading currency: Swiss franc on SIX, US dollar for ADRs

Novartis AG: core business model

Novartis AG positions itself as a global healthcare group focused primarily on patented prescription medicines in areas with high unmet medical need. After the completed separation of its generics and biosimilars business Sandoz, which was spun off and listed independently in 2023, the group’s strategic emphasis has shifted further toward innovative drugs with higher growth and margin potential, as reflected in company strategy updates published in 2024.

The business model rests on discovering, developing, manufacturing and marketing prescription therapies across key disease areas including oncology, cardiovascular, immunology, neuroscience and ophthalmology. Novartis invests heavily in research and development and relies on a mix of in-house discovery, clinical development and selective licensing or partnership agreements to broaden its pipeline and address new indications.

Revenues are generated mainly through the sale of branded medicines to hospitals, physicians and pharmacies, with pricing and reimbursement negotiated in each market. Large-scale commercial operations in the United States and Europe are especially important, as these regions account for a significant share of sales and profit due to their high healthcare spending and pricing levels.

Main revenue and product drivers for Novartis AG

In its innovative medicines segment, Novartis highlights a set of key blockbuster and near-blockbuster drugs as core growth engines. Cardiovascular therapy ENTRESTO, oncology treatments such as KISQALI and radioligand therapies, as well as immunology and neuroscience products, contribute materially to the company’s revenue base, according to recent earnings disclosures for fiscal 2024 and the first quarter of 2025.

Oncology remains one of the strategic pillars. Novartis markets targeted therapies and radioligand treatments for various cancers, seeking to expand indications through additional clinical trials. In parallel, the company invests in next-generation platforms including cell and gene therapies, although these remain a smaller portion of total sales compared with mainstream oncology and cardiovascular drugs.

Cardiovascular and metabolism therapies form another major pillar, where ENTRESTO and newer launches in heart failure and other indications are positioned to benefit from growing prevalence of chronic conditions worldwide. In immunology and neuroscience, Novartis pursues therapies for autoimmune diseases and neurological disorders, aiming to balance its portfolio across specialties and reduce dependency on any single therapeutic category.

Industry trends and competitive position

Novartis AG operates in a highly competitive global pharmaceutical market, where large multinationals compete to bring new therapies to patients under strict regulatory scrutiny. Patent protection, pricing pressures, biosimilar competition and regulatory timelines are constant factors shaping the competitive environment across regions including the United States, Europe and key emerging markets.

The focus on innovative medicines aligns Novartis with an industry trend where large pharma groups streamline portfolios and spin off lower-margin generics to sharpen research focus and capital allocation. With its dedicated oncology and cardiovascular franchises, Novartis competes with other global giants in therapeutic categories that see intense research investment but also offer sizable long-term growth opportunities.

At the same time, policy changes around drug pricing in the United States and Europe, including reimbursement reforms and value-based pricing approaches, can influence revenue trajectories. Companies such as Novartis need to demonstrate robust clinical and economic value for new launches to secure formulary access and reimbursement at sustainable price points over the long term.

Why Novartis AG matters for US investors

For US-based investors, Novartis AG is relevant both as an international blue-chip and as a healthcare stock with significant exposure to the American market. The group’s American Depositary Receipts trade on the New York Stock Exchange under the ticker NVS in US dollars, facilitating access through standard US brokerage accounts and retirement plans.

Novartis generates a substantial share of its revenue from the United States, where advanced oncology, immunology and cardiovascular therapies are widely used. This exposure links the company’s performance to trends in US healthcare spending, insurance coverage, hospital utilization and policy developments around Medicare and commercial payers.

In addition, many US investors seek global diversification within the healthcare sector. Novartis offers exposure to Swiss corporate governance, a strong balance sheet and a pipeline that is diversified across several therapeutic areas. At the same time, currency movements between the Swiss franc and US dollar can affect reported results for US holders of the ADRs, which is a factor to consider in performance assessment.

Conclusion

Novartis AG is in a phase of strategic focus following the Sandoz spin-off, concentrating more heavily on innovative medicines and oncology while maintaining a global commercial footprint. The company’s prospects are shaped by the success of key growth drivers, regulatory and pricing dynamics in major markets, and the ability to translate its research pipeline into approved therapies. For US investors, the stock offers exposure to a diversified global pharmaceutical group with a significant presence in the American healthcare system, although currency effects, regulatory changes and competitive pressures add layers of complexity and risk that need to be monitored over time.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.